Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1
Subjects
- Location of subjects
- Italy
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Graft versus host disease disease, graft-versus-host,disease, graft-VS-host,disease, homologous wasting,disease, runt,diseases, graft-versus-host,diseases, graft-VS-host,graft versus host disease,graft VS host disease,graft VS. host disease,graft-versus-host disease,graft-versus-host disease, resistance to,graft-versus-host disease, susceptibility to,graft-versus-host diseases,graft-versus-host-disease,graft-VS-host disease,graft-VS-host diseases,GVH,GVHD,GVHDS,homologous wasting disease,runt disease,Graft versus host disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- non-GvHD (Graft-versus-host disease)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- aGvHD (acute Graft-versus-host disease)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- pre-HSCT (hematopoietic stem cell transplant) samples of subjects who underwent HSCT who developed acute graft-versus-host disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 5
- Group 1 sample size Number of subjects in the case (exposed) group
- 5
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None.
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Roche454
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Source: Results (Text): Page 4, 3rd paragraph under sub-heading "aGvHD-associated gut microbiota signatures."
Description: Gut microbiota signatures in pre-HSCT samples of subjects who developed aGvHD compared to subjects who did not develop aGvHD (non-aGvHD)
Abundance in Group 1: decreased abundance in aGvHD (acute Graft-versus-host disease)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroidia |
Revision editor(s): WikiWorks, Chloe, ChiomaBlessing
Signature 2
Source: Results (Text): Page 4, 3rd paragraph under sub-heading "aGvHD-associated gut microbiota signatures."
Description: Gut microbiota signatures in pre-HSCT samples of subjects who developed aGvHD compared to subjects who did not develop aGvHD (non-aGvHD)
Abundance in Group 1: increased abundance in aGvHD (acute Graft-versus-host disease)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillota |
Revision editor(s): ChiomaBlessing
